Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.

Abstract

Pulmonary hypertension (PH) is a rare disease with a very poor prognosis. Certain pharmacologic approaches, which reduce pulmonary arterial pressure (PAP) and thereby prevent end-stage cardiopulmonary failure, have been used during recent years. Endothelin-1 has been found to be involved in the pathogenesis of PH. The dual endothelin-receptor antagonist… (More)

Topics

  • Presentations referencing similar topics